EMEA
MCID: JVN026
MIFTS: 24

Jeavons Syndrome (EMEA)

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Jeavons Syndrome

MalaCards integrated aliases for Jeavons Syndrome:

Name: Jeavons Syndrome 59
Eyelid Myoclonia with and Without Absences 59
Emea 59

Characteristics:

Orphanet epidemiological data:

59
jeavons syndrome
Age of onset: Childhood;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 34 G40.3
Orphanet 59 ORPHA139431

Summaries for Jeavons Syndrome

MalaCards based summary : Jeavons Syndrome, also known as eyelid myoclonia with and without absences, is related to juvenile absence epilepsy and epilepsy. The drugs Thrombin and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and liver.

Wikipedia : 75 Jeavons syndrome is a type of epilepsy. It is one of the most distinctive reflex syndromes of idiopathic... more...

Related Diseases for Jeavons Syndrome

Graphical network of the top 20 diseases related to Jeavons Syndrome:



Diseases related to Jeavons Syndrome

Symptoms & Phenotypes for Jeavons Syndrome

Drugs & Therapeutics for Jeavons Syndrome

Drugs for Jeavons Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Natalizumab Approved, Investigational Phase 4 189261-10-7
4
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
7
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
8
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Lopinavir Approved Phase 4 192725-17-0 92727
11
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
12
Nevirapine Approved Phase 4 129618-40-2 4463
13
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
14
Interferon beta-1b Approved Phase 4 145155-23-3
15
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
16
Cinacalcet Approved Phase 4 226256-56-0 156419
17
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
18
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
19
Dabigatran Investigational Phase 4 211914-51-1
20 Nucleic Acid Synthesis Inhibitors Phase 4
21 Hemagglutinins Phase 4
22 Vaccines Phase 4
23 Antithrombin III Phase 4
24 Antithrombins Phase 4
25 Serine Proteinase Inhibitors Phase 4
26 Anticoagulants Phase 4
27 Antiviral Agents Phase 4
28 interferons Phase 4
29 Antimetabolites Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Analgesics Phase 4
32 Hormones Phase 4
33 Hormone Antagonists Phase 4
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Antirheumatic Agents Phase 4
37 Anti-HIV Agents Phase 4
38 Anti-Retroviral Agents Phase 4
39 Cytochrome P-450 CYP3A Inducers Phase 4
40 Cytochrome P-450 Enzyme Inducers Phase 4
41 Cyclooxygenase Inhibitors Phase 4
42 Cyclooxygenase 2 Inhibitors Phase 4
43 Adjuvants, Immunologic Phase 4
44 Reverse Transcriptase Inhibitors Phase 4
45 Cytochrome P-450 CYP3A Inhibitors Phase 4
46 Cytochrome P-450 Enzyme Inhibitors Phase 4
47 Iron-Dextran Complex Phase 4
48 Interferon-beta Phase 4
49 Calcimimetic Agents Phase 4
50 Calcium, Dietary Phase 4

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations Completed NCT01306305 Phase 4
2 Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2009/2010-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations Completed NCT01306253 Phase 4
3 Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2008/2009-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations Completed NCT01303510 Phase 4
4 An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery Completed NCT01184989 Phase 4 Dabigatran etexilate
5 Open-label, Uncontrolled Postmarketing Study to Evaluate Immunogenicity, Safety and Tolerability of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Elderly Subjects Completed NCT01069367 Phase 4
6 Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study Completed NCT00942214 Phase 4 Natalizumab
7 Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) in the Management of Patient With Acute Stroke Within 3-hour After Their Symptom Onset Who Are Admitted to a Remote Hospital With no Stroke Unit Facility Completed NCT00279149 Phase 4
8 Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's Completed NCT00447759 Phase 4 Celecoxib;Diclofenac
9 A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent. Completed NCT00866021 Phase 4 Lopinavir/ritonavir;Lopinavir/ritonavir with two nucleoside analogs
10 Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. Completed NCT00455585 Phase 4 nevirapine, stavudine, lamivudine
11 De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
12 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
13 APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long Term Safety Of Tacrolimus Ointment For The Treatment Of Atopic Dermatitis Withdrawn NCT00368719 Phase 4 Tacrolimus
14 Clopidogrel Proton-Pump Inhibitors Study Withdrawn NCT01016717 Phase 4 Omeprazole;Pantoprazole
15 A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Adult Subjects Completed NCT00996138 Phase 2, Phase 3
16 Revaccination With Pneumococcal Conjugate Vaccine - Characterization Of The Immune Response After Polysaccharide Completed NCT00853749 Phase 3
17 Single and Multiple Dose Trial to Evaluate Pharmacokinetics, -Dynamics and Safety of iv Paracetamol in Preterm and Term Neonates Completed NCT00969176 Phase 2, Phase 3 paracetamol
18 A Phase III, Multicenter, Uncontrolled, Open Label Study to Evaluate Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects Completed NCT01161264 Phase 3
19 An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT01747330 Phase 3 Pancreatin
20 A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis Completed NCT01059344 Phase 3 Mesalamin
21 Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults Completed NCT00383539 Phase 3
22 Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly Completed NCT00383526 Phase 3
23 An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15μg) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older Completed NCT00554333 Phase 3
24 A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric Subjects Completed NCT01000207 Phase 2, Phase 3
25 Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis Completed NCT00794326 Phase 3 Solution for Peritoneal Dialysis
26 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation Completed NCT00434161 Phase 3 Palifermin before only;Placebo;Palifermin before and after
27 Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission Completed NCT02605720 Phase 3 Dihydroartemisinin-piperaquine
28 A Open-Label Study of the Transition to Rivaroxaban From Low-Molecular Weight Heparin for Venous Thromboembolism Prophylaxis After Total Joint Replacement: The Safe Simple Transitions Study Completed NCT01094886 Phase 3 Rivaroxaban
29 A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder Completed NCT00391222 Phase 3 Olanzapine;Placebo;Risperidone Long Acting Injectable (LAI)
30 TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome. Not yet recruiting NCT03357874 Phase 3 Clopidogrel;Ticagrelor
31 A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Not yet recruiting NCT03836014 Phase 3
32 Xenon-inhalation: Elimination of Xenon and Its Effect on Erythropoetin Levels in Blood of Healthy Volunteers Terminated NCT02129400 Phase 3 Xenon pro Anaesthesia 100 % (V/V);Aer medicinalis Linde 100%
33 Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure Terminated NCT01076816 Phase 3 dexmedetomidine
34 Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial Unknown status NCT01728818 Phase 2 Gemcitabine;Afatinib;Gemcitabine
35 Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer Unknown status NCT01019798 Phase 2 sunitinib, docetaxel, cisplatin
36 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
37 Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly Completed NCT00415129 Phase 2
38 Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Children Aged 10 to Less Than 18 Years Completed NCT01035749 Phase 2
39 Immunogenicity Study of the Influenza Vaccine in Adults Completed NCT00258934 Phase 2
40 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
41 A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes Completed NCT01305135 Phase 1, Phase 2 azacitidine and idarubicin
42 Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive. Completed NCT01503983 Phase 2 Trastuzumab;Capecitabine;Oxaliplatin
43 Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis Completed NCT01516203 Phase 2 AZD5847;Ethambutol, isoniazid, pyrazinamide, rifampin
44 Randomized, DB, Parallel Group, MC Study to Evaluate the Efficacy and Safety of Four Doses of Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depigoid Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma Completed NCT01144429 Phase 2
45 Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study With P144 Topical Adminsitration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00781053 Phase 2 P144 cream
46 Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis Completed NCT00574613 Phase 2 P144;placebo
47 Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 Vaccine and GlaxoSmithKline H1N1 Vaccine in Children 6 Months to 12 Years of Age Completed NCT00980850 Phase 2
48 Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI) Recruiting NCT03387475 Phase 2 Deferasirox
49 Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (EQol-MDS) Recruiting NCT02912208 Phase 2 Eltrombopag/Revolade
50 An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired Recruiting NCT01342952 Phase 2 Ambrisentan

Search NIH Clinical Center for Jeavons Syndrome

Genetic Tests for Jeavons Syndrome

Anatomical Context for Jeavons Syndrome

MalaCards organs/tissues related to Jeavons Syndrome:

41
Eye, Testes, Liver, Skin, Colon, Bone, Kidney

Publications for Jeavons Syndrome

Articles related to Jeavons Syndrome:

(show all 31)
# Title Authors PMID Year
1
Jeavons syndrome in a family with GLUT1-deficiency syndrome. 38
31352161 2019
2
Jeavons Syndrome: An Overlooked Epilepsy Syndrome. 38
30683501 2019
3
The electroclinical features of idiopathic generalized epilepsy patients presenting with fixation-off sensitivity. 38
30530446 2018
4
Prognosis of Juvenile myoclonic epilepsy with eye-closure sensitivity. 38
30248569 2018
5
Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. 38
30062784 2018
6
Jeavons Syndrome: Clinical Features and Response to Treatment. 38
30082241 2018
7
A case of de novo NAA10 mutation presenting with eyelid myoclonias (AKA Jeavons syndrome). 38
29957440 2018
8
Ongoing Photosensitivity in An Elderly Patient With Jeavons Sydrome. 38
29722743 2018
9
Crossing the lines between epilepsy syndromes: a myoclonic epilepsy variant with prominent eyelid myoclonia and atonic components. 38
29171397 2018
10
Clinical features and outcome of 6 new patients carrying de novo KCNB1 gene mutations. 38
29264397 2017
11
Prevalence of Pathogenic Copy Number Variation in Adults With Pediatric-Onset Epilepsy and Intellectual Disability. 38
28846756 2017
12
A prospective study of the modified Atkins diet for adults with idiopathic generalized epilepsy. 38
26588588 2015
13
Preliminary neurocognitive outcomes in Jeavons syndrome. 38
26492104 2015
14
Jeavons syndrome as an occipital cortex initiated generalized epilepsy: Further evidence from a patient with a photic-induced occipital seizure. 38
26552567 2015
15
[Jeavons syndrome: importance of differential diagnosis in epilepsy]. 38
24300557 2014
16
The visual system in eyelid myoclonia with absences. 38
25130932 2014
17
Levetiracetam as alternative treatment in Jeavons syndrome. 38
24798222 2014
18
Jeavons syndrome in China. 38
24495864 2014
19
[Antiepileptic drugs and seizure aggravation]. 38
25591652 2014
20
The hitchhiker's guide to the role of (transient) hypoglycemia in refractory seizures and epilepsy. 38
22759689 2012
21
[Clinical and electroencephalographic characteristics of Jeavons syndrome]. 38
22931943 2012
22
Jeavons syndrome existing as occipital cortex initiating generalized epilepsy. 38
21729035 2011
23
10-year outcome of childhood epilepsy in well-functioning children and adolescents. 38
21371918 2011
24
Oxcarbazepine induced worsening of seizures in Jeavons syndrome: lessons learnt from an interesting presentation. 38
21339665 2011
25
Benign myoclonic epilepsy of infancy evolving to Jeavons syndrome. 38
20691946 2010
26
[Does Jeavons syndrome exist? A report of a series of 10 cases]. 38
20473833 2010
27
Eyelid myoclonia with absences (Jeavons syndrome): a well-defined idiopathic generalized epilepsy syndrome or a spectrum of photosensitive conditions? 38
19469840 2009
28
Absence status epilepticus in monozygotic twins with Jeavons syndrome. 38
18782694 2008
29
A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). 38
18248445 2008
30
Unusual features in eyelid myoclonia with absences: a patient with mild mental retardation and background slowing on electroencephalography. 38
16446119 2006
31
Syndromes of idiopathic generalized epilepsies not recognized by the International League Against Epilepsy. 38
16302876 2005

Variations for Jeavons Syndrome

Expression for Jeavons Syndrome

Search GEO for disease gene expression data for Jeavons Syndrome.

Pathways for Jeavons Syndrome

GO Terms for Jeavons Syndrome

Sources for Jeavons Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....